ataluren

Details

Generic Name:

ataluren

Project Status:

Cancelled

Manufacturer:

PTC Therapeutics Canada ULC

Call for patient/clinician input open:

March 5, 2019

Brand Name:

Translarna

Project Line:

Reimbursement Review

Project Number:

SR0607-000

Call for patient/clinician input closed:

April 24, 2019

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

For the treatment of dystrophinopathy resulting from a nonsense mutation in the dystrophin gene.

Submission Type:

New

Fee Schedule:

Pending

Indications:

Dystrophinopathy

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Last Updated : March 5, 2019